FDA approves DUCORD product for stem cell transplants

DUCORD is approved for use in hematopoietic stem cell transplantation for patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.

"This approval and the quality it reinforces are lynchpins in Duke Medicine's commitment to developing and translating innovative cellular therapies," said Victor J. Dzau, M.D., chancellor for health affairs at Duke University and president and CEO of Duke University Health System.

Read the full article on Medical Xpress